Table 3.
The roles of KDM4A in tumorigenesis.
| Cancer type | Target genes/ligand proteins | Functions | References |
|---|---|---|---|
| Leukemia | TPM2, SLC29A2, CD82 | Promoting promotes their self-renewal, proliferation, and survival during leukemogenesis, and sensitizing to chemical agents | 49, 50, 51, 52, 53 |
| Lung cancer | CHD5, CXCL5, ADAM12, JAG1 | Promoting transformation, proliferation, invasion, metastasis, and drug resistance | 62, 63, 64 |
| Breast cancer | c-Jun, cyclin D1 | Promoting progression of breast cancer, and associated with breast cancer grade, TNM stage, histological type, and disease-free survival | 104 |
| PCa | PSA, YAP1, MMP1, PSMD10, MMP7, PDK1, PDK3 | Promoting the progression of prostate cancer | 90, 91, 92,94, 95, 96, 97, 98, 99 |
| GC | CCDC8 | Promoting growth and invasion of GC and sensitizing GC cells to cisplatin, 5-FU, and docetaxel | 102,104 |
| HCC | miR-372, Pim 1, p21 | Accelerating malignant progression of HCC | 106, 107, 108 |
| CRC | RASSF1A, 53BP1 | Sensitizing chemotherapy-induced cell death and leading to genomic integrity | 110,112,113 |
| PDAC | miR-137, RFXAP | Promoting proliferation | 114,115 |
| Bladder cancer | ADAM12, SLUG | Promoting muscle invasion, extravesical extension, and lymph node metastasis | 62,118 |
| Cervical cancer | miR-491-5p, HIF1α, TfR1, DMT1 | Promoting proliferation and inhibiting ferroptosis | 119,120 |
| Renal carcinoma | Ribosomal protein-coding genes | Sustaining tumor cell survival under amino acid deprivation | 121 |
| OS | SLC7A11 | Promoting drug resistance and lung metastasis by reducing ferroptosis | 122 |
| HNSCC | JUN and FOS | Promoting invasion, and metastasis | 124 |
| EC | c-MYC, AR, p27 | Promoting proliferation, invasion, and metastasis | 126,127 |